F-Tag Library On-Demand Series-[UPDATED!] F757 Drug Regimen Is Free From Unnecessary Drugs

Video Transcription

Video Summary

This presentation covers F757, a regulatory requirement ensuring residents' drug regimens are free from unnecessary drugs, addressing excessive doses, duplicate therapies, and inadequate monitoring or indications. F757 applies broadly to all medications, complementing F758, which focuses on psychotropics. The updated CMS guidelines emphasize managing residents' medication regimens to promote their overall well-being with documented clinical rationale and resident consent.<br /><br />Key factors include careful evaluation of the resident’s physical, mental, behavioral, and psychosocial status, avoiding medications for conditions expected to resolve naturally or due to environmental or psychological stressors alone. Facilities must review medications upon admission, condition changes, pharmacist reviews, or emergencies. Monitoring for adverse effects is critical, utilizing tools like BEERS criteria and the CMS adverse drug event trigger tool.<br /><br />Non-compliance can range from no harm to immediate jeopardy, with severity levels guiding citations. To regain compliance, facilities perform root cause analysis, develop corrective actions addressing affected and potential residents, revise policies, train staff comprehensively, and implement a monitoring plan with decreasing audit frequency. Regular audits cover medication appropriateness, documentation, education, and adverse event monitoring.<br /><br />Resources from APACN and CMS assist compliance. Leadership must ensure systemic changes, ongoing staff competency, and resident rights to informed consent and participation in treatment decisions, thereby improving medication safety and resident quality of life.

Keywords

F757 regulatory requirement

unnecessary drugs

medication regimen review

CMS guidelines

adverse drug event monitoring

root cause analysis

resident informed consent